Related Experiment Video
Updated: Aug 7, 2025

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
Published on: April 8, 2016
Erythrodermic Psoriasis Successfully Treated with Anti IL-17: A Case Series
Nicoletta Bernardini, Nevena Skroza1, Ilaria Proietti
1Nevena Skroza, MD, Dermatology Unit "Daniele Innocenzi" Dept. of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome - Polo Pontino (LT), nevena.skroza@uniroma1.it.
Abstract:
Erythrodermic psoriasis (EP) is a very rare but extremely severe subtype of chronic plaque psoriasis. Its pathogenesis still remains unknown, and current therapeutic strategies frequently end in failure. Erythrodermic psoriasis often requires hospitalization in order to control any kind of possible serious complications. Treatment of EP is a challenge for clinicians because international guidelines are lacking. Nevertheless, Th17 has been shown to be the second-most predominant T-cell type after Th2 in EP lesions. There is a growing body of evidence supporting the safety and efficacy of biologics in rapidly achieving near-total clearance of EP, particularly within the IL-17 class. Herein we report a series of 5 cases of EP successfully treated with anti-interleukines 17: Ixekizumab and Secukinumab.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

